RxDoctor Payments Data

Todd Smith, DO

Internal Medicine · Princeton, WVNPI 1780649889

Payments from drug & device makers

$1,015in general payments, 2019–2025

Across 58 payments — averaging $17.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$199
  • Boehringer Ingelheim$190
  • Averitas Pharma Inc.$132
  • Amgen$97
  • Novo Nordisk$76
  • AstraZeneca$68
  • plus $252 from 12 others

What the payments were for

  • Food & beverage$1,015100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,015 in reported general payments places this provider in the 70th percentile of 573 internal medicine providers in West Virginia.

See all internal medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$181,227
Medicare patients
422
Services billed
4,693

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide273$346,810
EliquisApixaban217$195,330
OzempicSemaglutide89$96,981
JardianceEmpagliflozin65$72,814
XareltoRivaroxaban57$60,327
Repatha SureclickEvolocumab52$36,677
JanuviaSitagliptin Phosphate40$34,660
LinzessLinaclotide30$29,606
MyrbetriqMirabegron41$29,486
EntrestoSacubitril/Valsartan26$26,466
TrulicityDulaglutide17$23,060
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$21,365
FarxigaDapagliflozin Propanediol13$20,063
Breo ElliptaFluticasone/Vilanterol43$19,703
Tresiba Flextouch U-200Insulin Degludec14$17,862

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$14$369,870290 claims
PfizerEliquis, Premarin, Dilantin$26$210,545250 claims
Novo NordiskOzempic$76$96,98189 claims
Boehringer IngelheimJardiance, Tradjenta$190$82,80783 claims
MerckJanuvia, Janumet$50$48,16757 claims
GSKTrelegy Ellipta, Breo Ellipta$20$41,06965 claims
AbbVieLinzess, Synthroid$199$38,281154 claims
NovartisEntresto$18$26,46626 claims
AstraZenecaFarxiga, Symbicort$68$25,74128 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 573 internal medicine providers in West Virginia.

Other internal medicine in Princeton

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →